Reference no: EM133476314
Question 1: What advantage do liposomes offer during systemic administration of a therapeutic RNA?
Question 2: What two advantages does RNA have over DNA as a therapeutic molecule?
From your S290 studies:
Question 3: Briefly explain what is meant by the term 'non-coding RNAs'. TWO examples of types of non-coding RNA that you have met in your S290 studies and briefly describe the function of each type.
Question 4: What are liposomes and how are they taken up into a cell?
Question 5: From your reading of the TYPES OF RNA THERAPY section:
Question 6: What two effects do modifications offer to antisense oligos?
Several approaches to the treatment of Duchenne muscular dystrophy (DMD) are discussed by the author.
i.What is the most recent FDA-approved ASO drug approved for treatment of DMD and when was it approved?
ii.How does the therapeutic ASO Eteplirsen exert its effect and to what type of patient is this drug targeted?
Question 7: How do aptamers exert their biological effect?
Question 8: Which protein is targeted using pegaptanib?
Question 9: What two reasons are given by the author for the ability to produce COVID-19 vaccines rapidly?
Question 10: What does the author suggest as a route for personalised medicine for targeting tumours?